The trial is executed in collaboration with Presidio Pharmaceuticals.

Boehringer Ingelheim completes individual enrolment for interferon-free of charge hepatitis C treatment Boehringer Ingelheim today announced the completion of individual enrolment for a Stage IIa clinical trial investigating a fresh interferon-free, all-oral, direct-performing antiviral mixture treatment for sufferers with genotype-1a chronic hepatitis C virus disease. The trial is executed in collaboration with Presidio Pharmaceuticals, Inc.The decreased revenue in Q4-2010, in comparison with Q4-2009 was partially offset by lower R&D expenditures and foreign exchange loss. At December 31 Liquidity and Outstanding Talk about Capital, 2010, the business had cash and money equivalents of $76.9 million.53 per share.. Mirkin lab, Northwestern Scientists have developed a nanotechnology-based method to silence an integral genetic switch mixed up in formation of glioblastoma human brain malignancy.